VS-4718

DRUG2 trials

Sponsors

Verastem, Inc.

Conditions

Metastatic CancerNon Hematologic CancersRelapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Phase 1

Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies

TerminatedNCT01849744

Verastem, Inc.Metastatic Cancer, Non Hematologic Cancers

Start: 2013-06-30End: 2017-06-30Updated: 2017-07-28

Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia

WithdrawnNCT02215629

Verastem, Inc.Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

End: 2016-11-30Updated: 2017-01-27

Related Papers

VS-4718, a Potent Focal Adhesion Kinase (FAK) Inhibitor, Exhibits Anticancer Activity in Leukemia Models in Vitro and in Vivo

Blood2014-12-063 citations